Pathogenic autoantibodies and circulating immune mediators

Pathogenic autoantibodies and circulating immune mediators represent a broad category of soluble factors that drive the pathogenesis of various autoimmune and inflammatory disorders [Ludwig et al., 2017; Frontiers in Immunology]. Autoantibodies are immunoglobulins that inappropriately target self-antigens, leading to tissue damage through complement activation, opsonization, or interference with receptor function [Diamond & Lipsky, 2022; Harrison's Principles of Internal Medicine]. These molecules are hallmark features of conditions such as Myasthenia Gravis, where they target the neuromuscular junction, and Systemic Lupus Erythematosus (SLE), where they target nuclear antigens [Diamond & Lipsky, 2022]. Circulating immune mediators, such as cytokines (e.g., TNF, IL-6) and complement proteins, act as signaling molecules that amplify inflammatory cascades and recruit immune cells to sites of injury [Dinarello, 2007; European Journal of Immunology]. Therapeutic strategies targeting these entities include direct neutralization with monoclonal antibodies, physical removal via plasma exchange, or the depletion of the B-cell populations responsible for autoantibody production [Chan & Carter, 2010; Nature Reviews Immunology]. Additionally, intravenous immunoglobulin (IVIG) is often used to neutralize autoantibodies and modulate the immune response [Reeves & Winters, 2014; Journal of Clinical Apheresis]. While effective in managing systemic inflammation and organ-specific damage, modulating these factors often carries risks of significant immunosuppression and opportunistic infections [Winthrop, 2017; Nature Reviews Rheumatology]. Consequently, patient selection and monitoring of biomarkers like C-reactive protein and specific antibody titers are essential for optimizing therapeutic outcomes [Ludwig et al., 2017].

Other names

Self-reactive antibodiesAuto-antibodiesInflammatory cytokinesHumoral immune factorsSoluble immune mediatorsPathogenic immunoglobulins

Therapeutic strategies include the depletion of antibody-producing B-cells to prevent autoantibody synthesis, direct neutralization of circulating cytokines or complement proteins by monoclonal antibodies, and the physical removal of these mediators from the blood via therapeutic plasma exchange (apheresis) [Chan & Carter, 2010; Nature Reviews Immunology; Reeves & Winters, 2014; Journal of Clinical Apheresis].